China Life Insurance Co Ltd (CILJF)

Price$3.89Cached quoteAs of 2026-09-05 13:20 UTC

AI: Undervalued

Price checkThe shares look undervalued unless recent profits collapse far below already-cyclical history.

At the observed OTC quote, China Life trades at roughly five times 2025 profit per share and about 1.2 times year-end shareholder equity per share. Even using 2024 profit, which was materially lower, the multiple remains only around seven times earnings. First-half 2026 profit is expected at RMB128.9-137.1 billion, already close to 2025's RMB154.1 billion full-year result. The discount therefore assumes much of today's investment-driven profit will reverse, plus a substantial China-specific risk premium.

Big pictureProfit and cash generation improved sharply, but investment markets still drive unusually large swings.

The supplied SEC-derived history shows operating cash flow stayed positive from 2017 through 2022, reaching RMB352.0 billion in 2022 versus RMB286.4 billion in 2021. By 2025, operating cash inflow reached RMB459.9 billion, up 21.4% year over year. For an insurer, this is not ordinary free cash flow because premiums are invested to meet future policy claims. Earnings are visibly cyclical: net income ranged from RMB11.4 billion in 2018 to RMB154.1 billion in 2025.

Business strengthChina Life combines huge scale, strong solvency, and rising new-business value with modest shareholder payouts.

China Life ended 2025 with RMB7.59 trillion of assets and RMB595.2 billion of shareholder equity. Its core and comprehensive solvency ratios were 128.8% and 174.0%; solvency measures whether an insurer has enough capital for promised claims. New-business value, an estimate of profit created by newly sold policies, rose 35.7% to RMB45.75 billion. Annual dividends increased 31.7% to RMB24.2 billion, yet consumed only about 16% of reported profit. No buyback evidence appears in the supplied history, and missing share-count data limits direct dilution testing.

What could change the storyA reversal in equity gains or weaker insurance sales would quickly challenge today’s cheap-looking valuation.

The strongest bull case is improving insurance economics alongside a low valuation: 2025 new-business value rose 35.7%, guaranteed rates on new liabilities have been falling, and capital remains ample. The strongest bear case is earnings quality. China Life's 2026 first-half profit forecast implies 215%-235% growth, while Caixin reported that technology-related equity gains were a major driver. A sustained fall in Chinese equities, or new-business value turning negative year over year, would weaken the assumption that normalized earnings justify even today's low multiple.

AI: News

Profit forecast triplesChina Life forecast a dramatic first-half profit jump, strengthening expectations for earnings and possible dividends.

On July 14, China Life estimated first-half 2026 net profit of RMB128.9-137.1 billion, up about 215%-235% from RMB40.9 billion a year earlier. That scale exceeded many prior full-year expectations. Caixin reported that strong equity-market returns, especially technology-related holdings, were a major contributor. This matters because higher profit increases capital and dividend capacity, but it also warns investors that the gain may be less repeatable than growth produced by insurance sales alone.

Offshore insurance tax enforcementStricter taxation of offshore policies could redirect some mainland demand toward domestic insurers such as China Life.

Reuters reported on August 6 that mainland authorities had begun enforcing a 20% personal-income tax on returns from offshore insurance policies, including products bought in Hong Kong. Hong Kong-focused insurers fell sharply that day. China Life is primarily a mainland insurer, so reduced after-tax appeal for offshore savings products could improve its competitive position. That benefit remains uncertain: the rule directly targets customer economics rather than guaranteeing sales transfers, and no reliable evidence yet proves a measurable China Life volume gain.

Weak quarter shakes sharesA weak fourth quarter triggered a sharp selloff despite record annual profit, exposing earnings sensitivity.

After the March 25 annual results, China Life's Hong Kong shares fell nearly 8% on March 26 while its Shanghai shares dropped more than 5%, according to Investing.com. Full-year net profit had risen 44.1% to RMB154.1 billion, but investors focused on weaker fourth-quarter performance. The episode is important because it shows the market already discounts headline profit when investment results appear unsustainable. It also supports using normalized, multi-year earnings rather than treating one exceptional year as permanent.

Loading local price history

Revenue

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Net income

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Free cash flow

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Total cash / debt

CashTotal debt

2015

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

Financial statements

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	¥605.11B	¥302.92B	¥396.47B	¥804.39B	¥824.93B	¥805.05B	¥729.50B	¥627.42B	¥643.36B	¥540.78B	¥507.45B
Net income	¥154.08B	¥106.94B	¥51.18B	¥33.51B	¥52.26B	¥51.34B	¥59.01B	¥11.94B	¥32.75B	¥19.59B	¥35.19B
Net profit margin	25.46%	35.30%	12.91%	4.17%	6.33%	6.38%	8.09%	1.90%	5.09%	3.62%	6.93%
Basic EPSper basic share	CN¥5.45	CN¥3.78	CN¥1.81	CN¥1.14	—	CN¥1.77	CN¥2.05	CN¥0.39	CN¥1.13	CN¥0.66	CN¥1.22
Diluted EPSper diluted share	CN¥5.45	CN¥3.78	CN¥1.81	CN¥1.14	—	CN¥1.77	CN¥2.05	CN¥0.39	CN¥1.13	CN¥0.66	CN¥1.22